Abstract
Non-Hodgkin lymphoma (NHL) is a genetically heterogeneous disease with several oncogenic events implicated in the transformation of normal developing B lymphocytes. The objective of this study was to elucidate the signal transduction-based antitumor mechanism(s) of action for the anti-CD40 monoclonal antibody dacetuzumab (SGN-40) in NHL. We report that dacetuzumab activates two distinct proapoptotic signaling pathways, overcoming transformation events key to the pathogenesis of NHL. Dacetuzumab-mediated CD40 signaling constitutively activated the nuclear factor-κB and mitogen-activated protein kinase signaling pathways producing the sustained downregulation of B-cell lymphoma 6 (BCL-6), an oncoprotein implicated in lymphomagenesis. Loss of BCL-6 resulted in c-Myc downregulation and activation of a transcriptional program characteristic of early B-cell maturation, concomitant with reduced proliferation and cell death. In a second mechanism, dacetuzumab signaling induced the expression of the proapoptotic p53 family member TAp63α and downstream proteins associated with the intrinsic and extrinsic apoptotic machinery. Dacetuzumab was synergistic in combination with DNA-damaging chemotherapeutic drugs, correlating with TAp63α upregulation. Furthermore, dacetuzumab augmented the activity of rituximab in combination with multiple chemotherapies in the xenograft models of NHL. The ability of dacetuzumab signaling to circumvent oncogenic events and potentiate the activity of chemotherapy regimens provides a unique therapeutic approach to NHL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kuppers R . Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251–262.
Ye BH, Rao PH, Chaganti RS, Dalla-Favera R . Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res 1993; 53: 2732–2735.
Weiss LM, Warnke RA, Sklar J, Cleary ML . Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987; 317: 1185–1189.
Ladanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RS . MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood 1991; 77: 1057–1063.
Gronbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998; 92: 3018–3024.
Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997; 90: 4078–4091.
Biancone L, Cantaluppi V, Camussi G . CD40-CD154 interaction in experimental and human disease (review). Int J Mol Med 1999; 3: 343–353.
van Kooten C, Banchereau J . CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2–17.
Harnett MM . CD40: a growing cytoplasmic tale. Sci STKE 2004; 2004: pe25.
Ramesh N, Morio T, Fuleihan R, Worm M, Horner A, Tsitsikov E et al. CD40-CD40 ligand (CD40L) interactions and X-linked hyperIgM syndrome (HIGMX-1). Clin Immunol Immunopathol 1995; 76 (3 Part 2): S208–S213.
Guzman-Rojas L, Sims-Mourtada JC, Rangel R, Martinez-Valdez H . Life and death within germinal centres: a double-edged sword. Immunology 2002; 107: 167–175.
Vonderheide RH . Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007; 13: 1083–1088.
Aggarwal BB . Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745–756.
Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ . Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000; 164: 2200–2206.
Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994; 83: 2787–2794.
Coiffier B . Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603–3613.
Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH . Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14 (Suppl 1): i5–10.
Tong AW, Stone MJ . Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003; 10: 1–13.
Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005; 65: 8331–8338.
Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M et al. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer 2009; 100: 113–117.
Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM . The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000; 6: 4950–4956.
Allman D, Jain A, Dent A, Maile RR, Selvaggi T, Kehry MR et al. BCL-6 expression during B-cell activation. Blood 1996; 87: 5257–5268.
Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007; 12: 280–292.
Jardin F, Ruminy P, Bastard C, Tilly H . The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. Pathol Biol (Paris) 2007; 55: 73–83.
Niu H, Ye BH, Dalla-Favera R . Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev 1998; 12: 1953–1961.
Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL . Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004; 173: 1158–1165.
Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 2007; 8: 705–714.
Phan RT, Dalla-Favera R . The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432: 635–639.
Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R . BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005; 6: 1054–1060.
Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G et al. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 2006; 108: 3450–3457.
Lantner F, Starlets D, Gore Y, Flaishon L, Yamit-Hezi A, Dikstein R et al. CD74 induces TAp63 expression leading to B-cell survival. Blood 2007; 110: 4303–4311.
Chou TC, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55.
Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 2005; 24: 2458–2471.
Kelly KF, Daniel JM . POZ for effect—POZ-ZF transcription factors in cancer and development. Trends Cell Biol 2006; 16: 578–587.
Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T et al. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci USA 2004; 101: 14198–14203.
Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula SV, Shen Q et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005; 7: 445–455.
Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 2009; 113: 3397–3405.
Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med 2009; 15: 1369–1376.
Burington B, Yue P, Shi X, Advani R, Yu N, Lau J et al. CD40 Pathway activation status predicts response to CD40 targeted therapy in diffuse large B cell lymphoma. Sci Transl Med 2011 (in press).
Marshall CJ . Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179–185.
Whalen AM, Galasinski SC, Shapiro PS, Nahreini TS, Ahn NG . Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol Cell Biol 1997; 17: 1947–1958.
Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 2009; 16: 324–335.
Shapiro-Shelef M, Lin KI, Savitsky D, Liao J, Calame K . Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med 2005; 202: 1471–1476.
Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002; 17: 51–62.
Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH . Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 2003; 4: 321–329.
Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, Gravallese EM et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001; 412: 300–307.
Lin KI, Lin Y, Calame K . Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro. Mol Cell Biol 2000; 20: 8684–8695.
Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305–316.
Li Y, Zhou Z, Chen C . WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ 2008; 15: 1941–1951.
Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207–4213.
Acknowledgements
We thank Dr Hans-Peter Gerber for optimization of in vivo chemotherapy regimens.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
All authors are employees and shareholders of Seattle Genetics, Inc.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Lewis, T., McCormick, R., Stone, I. et al. Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells. Leukemia 25, 1007–1016 (2011). https://doi.org/10.1038/leu.2011.21
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.21